LXRX is the only one who thinks hitting SGLT1 is a good idea. Everyone else is trying to avoid. Isis even made SGLT2 their only pipeline candidate that is competing directly against more advanced small molecules because SGLT2 is such a difficult drug target. Time will tell who is right (if anyone).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.